Hospital
Prime Healthcare Services - Gadsden LLC
Prime Healthcare Services - Gadsden LLC was paid $3.90M by Medicaid between Jan 2018 and Dec 2024, across 75 billing codes. Its largest line is 99285, emergency room visit (most serious) — 52% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES - GADSDEN LLC
GADSDEN, AL 35901
GADSDEN, AL 35901
33aNPI1992103857assigned 12/09/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.90M
24GClaims124,656
24DCodes billed75
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alabama
Rank by total paid#18 of 77
Median peer was paid$1.13M
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,351 | $627K | |
| 2019 | 21,012 | $581K | |
| 2020 | 10,863 | $296K | |
| 2021 | 14,009 | $360K | |
| 2022 | 18,446 | $549K | |
| 2023 | 22,676 | $844K | |
| 2024incomplete | 15,299 | $644K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 52% | 9,761 | 8,220 | $2.02M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 12,978 | 11,401 | $700K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 14,066 | 12,472 | $511K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.5% | 14,041 | 11,648 | $96K |
| 80053 | Comprehensive metabolic panel | 2.3% | 10,637 | 8,942 | $91K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.6% | 289 | 248 | $63K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 5,923 | 4,867 | $50K |
| 87428 | 1.2% | 968 | 774 | $46K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,537 | 1,671 | $36K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 431 | 351 | $30K |
| 84484 | <1% | 3,636 | 2,592 | $25K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,031 | 4,218 | $22K |
63 more codes
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,359 | $19K |
| 83690 | <1% | 2,704 | $17K | |
| 81001 | <1% | 5,032 | $17K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 413 | $16K |
| 93458 | <1% | 53 | $13K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 331 | $13K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 159 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,572 | $11K |
| 87486 | <1% | 301 | $10K | |
| 87581 | <1% | 299 | $10K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 301 | $10K |
| 81025 | <1% | 3,106 | $10K | |
| 87070 | <1% | 820 | $9K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 47 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 836 | $7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 134 | $7K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 189 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,525 | $4K |
| 81003 | <1% | 1,137 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,026 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 472 | $2K |
| 83880 | <1% | 88 | $2K | |
| 85610 | <1% | 446 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 66 | $962.50 |
| 87081 | <1% | 97 | $869.46 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 109 | $794.95 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 67 | $566.16 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,245 | $564.47 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,978 | $486.76 |
| 82553 | <1% | 31 | $417.05 | |
| 80061 | Lipid panel | <1% | 46 | $352.45 |
| 82550 | <1% | 31 | $235.37 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 434 | $190.18 |
| 85379 | <1% | 25 | $189.99 | |
| 85027 | <1% | 94 | $185.60 | |
| 85730 | <1% | 196 | $169.36 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 105 | $166.74 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 14 | $148.72 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 18 | $131.05 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14 | $127.26 |
| 83735 | <1% | 17 | $115.40 | |
| 83605 | <1% | 14 | $78.47 | |
| 82565 | <1% | 55 | $60.48 | |
| 80076 | <1% | 13 | $50.16 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 818 | $44.02 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 16 | $37.18 |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,368 | $18.53 |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 875 | $18.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 85 | $17.65 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 396 | $14.14 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 986 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 55 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 217 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 226 | $0.00 |
| 99406 | 0% | 29 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 151 | $0.00 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 189 | $0.00 |
| 99152 | 0% | 212 | $0.00 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 255 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 264 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 16 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 169 | $0.00 |
| A4221 | Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (MANAGING ASSOCIATE GENERAL COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.